Navigation Links
Neurocrine Biosciences To Present At Deutsche Bank 2013 Biofest And The 25th Annual Piper Jaffray Healthcare Conference
Date:11/26/2013

SAN DIEGO, Nov. 26, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at two investor conferences next week.  

On December 3 at 2:15pm Eastern Time (11:15am Pacific Time) he will make a presentation at the Deutsche Bank 2013 Biofest in Boston. 

On December 4 at 11:30am Eastern Time (8:30am Pacific Time) he will make a presentation at the 25th Annual Piper Jaffray Healthcare Conference in New York City. 

Both webcasts may be accessed live on the Company's website at http://www.neurocrine.com. Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentations will be available on the website approximately one hour after the conclusion of each event and will be archived for one month.

Neurocrine Biosciences, Inc. is a clinical stage drug discovery company primarily focused on neurological and endocrine based diseases and disorders. The Company discovers and develops innovative pharmaceuticals, in diseases with high unmet medical needs or where the existing drug classes are inadequate, through a disciplined yet entrepreneurial process. Utilizing a portfolio approach to drug discovery, Neurocrine has multiple small molecule drug candidates at various stages of pharmaceutical development. Neurocrine's two lead late stage clinical programs are elagolix, a GnRH antagonist for women's health that is partnered with AbbVie Inc., and a wholly owned VMAT2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company.  Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Neurocrine Biosciences Reports Third Quarter 2013 Results
2. Neurocrine Biosciences Reports Second Quarter 2013 Results
3. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2013 Financial Results
4. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
5. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
6. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
7. Neurocrine Biosciences Reports Third Quarter 2012 Results
8. Neurocrine Biosciences Reports Second Quarter 2012 Results
9. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
10. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
11. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Feb. 24, 2017 Symic Bio, a biopharmaceutical ... new category of therapeutics, announced today the completion of ... peripheral artery disease. The trial will evaluate the safety ... in the reduction of restenosis following angioplasty. ... milestone for SB-030," said Nathan Bachtell , M.D., ...
(Date:2/24/2017)... -- China Cord Blood Corporation (NYSE: CO ... cord blood collection, laboratory testing, hematopoietic stem cell processing ... financial results for the third quarter and first nine ... Third Quarter of Fiscal 2017 Highlights ... 2017 increased by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the ... today announced its financial results for the fourth quarter and ... Financial Highlights Total sales in the ... or increased by 13.6% in USD terms to $77.6 million ... Gross profit increased by 13.3% to $46.8 million ...
(Date:2/24/2017)... SAN DIEGO , Feb. 24, 2017  OncoSec ... intratumoral cancer immunotherapies, will host a Key Opinion Leader ... featured as an oral and poster presentation at the ... development plan. The KOL event will be held in-person ... 12:00 PM EST / 9:00 AM PST at the ...
Breaking Biology Technology:
(Date:2/8/2017)... , Feb. 8, 2017 About Voice Recognition ... to match it against a stored voiceprint template. ... pitch, cadence, and tone are compared to distinguish ... hardware installation, as most PCs already have a ... transactions. Voice recognition biometrics are most likely to ...
(Date:2/8/2017)... 2017 Report Highlights The global ... $8.3 billion in 2016 at a compound annual growth ... Report Includes - An overview of the global market ... data from 2015 and 2016, and projections of compound ... the market on the basis of product type, source, ...
(Date:2/6/2017)... DENVER , Feb. 6, 2017 ... national security are driving border authorities to continue ... Acuity reports there are 2143 Automated Border Control ... Kiosks currently deployed at more than 163 ports ... between 2013 to 2016 achieving a combined CAGR ...
Breaking Biology News(10 mins):